- Research article
- Open Access
Hospitalisation for rotavirus gastroenteritis in the paediatric population in the Veneto Region, Italy
BMC Public Health volume 10, Article number: 636 (2010)
This study evaluates the epidemiological impact of RVGE hospitalisation in the Veneto Region during the period spanning from 2000-2007 along with the associated costs. The analysis was conducted in an area where rotavirus vaccination is not included into immunization programmes and is an attempt to assess the potential benefits of such introduction.
To update the estimates of acute RVGE hospitalisation rates in children ≤5 years in the Veneto Region, we conducted an 8 year retrospective observational population-based analysis (2000-2007).
Over the study period, a total of 4,119 admissions for RVGE were reported, with a mean hospital stay of 3.5 days. The population-based hospitalisation RVGE incidence rate was 195.8 per 100,000 children aged ≤5 years (lower than other European countries).
RVGE is an important cause of paediatric hospitalisation in the Veneto Region. The data reaffirm the substantial burden of rotavirus hospitalisations in children and the potential health benefits of the vaccination as well as the possibility of adding rotavirus vaccination to the current schedule.
Rotavirus is the main cause of severe acute gastroenteritis (AGE) among children ≤5 years [1, 2]. Improvements in sanitation and hygiene have not changed the global incidence of this disease, pointing to vaccination as the most effective way to achieve disease control [3, 4]. Worldwide, the incidence of rotavirus gastroenteritis (RVGE) is similar both in developed and developing countries [2, 5].
In industrialised countries, where access to health care is generally good, mortality due to RVGE is very low [6, 7]. Nevertheless, the burden of disease remains considerable, being a major cause of hospitalization among children. In these countries, a model developed by the European Centre for Disease Prevention and Control estimates an overall rotavirus hospitalisation rate of 445 per 100,000 children younger than 5 years of age .
Globally, rotavirus is more common in the cooler months, but seasonal peaks can vary broadly and may occur from autumn to spring [8, 9]. Rotavirus is primarily transmitted by fecal-oral route and is highly contagious. Almost all children are infected at least once before the age of 5 . Its typical symptoms vary from a mild illness with self-limiting watery diarrhoea to severe diarrhoea accompanied by vomiting and fever, with risks of dehydration .
Gastrointestinal infections in children have a significant impact on the families and on society. They result in increased medical expenditures, lost productivity and childcare .
Vaccination is considered the most effective public health strategy to prevent rotavirus infection and reduce disease burden, so that the World Health Organisation strongly recommends inclusion of rotavirus vaccines into national immunisation programs in the regions where vaccine efficacy data suggest a significant public health impact and where appropriate infrastructure and finance mechanisms are available .
This study evaluates the epidemiological impact of RVGE hospitalisation in the Veneto Region during the period spanning from 2000-2007 along with the associated cost. The analysis was conducted in an area where rotavirus vaccination is not included into immunization programmes and is an attempt to assess the potential benefits of such introduction.
To estimate the annual rates of RVGE associated hospitalization a retrospective population-based study was conducted analysing data collected from the hospital discharge database (HDD) of the Veneto Region (North East Italy), covering the 100% of discharges from all hospitals. The data were acquired in electronic form and were anonymous. The population used as denominator comes from the 2001 census data (National Institute of Statistics) and for the remaining years from the Office for Regional Statistics.
Cases of RVGE were identified using the International Classification of Diseases, nine revision, Clinical Modification (ICD-9-CM). Acute gastroenteritis discharges were identified by the codes ICD-9-CM 001 to 009, whereas RVGE discharges were identified by the code 008.61, eliminating secondary diagnosis so as to exclude nosocomial cases . AGE cases of unspecified etiology were identified by code 009.1. The hospitalisation incidence due to rotavirus gastroenteritis and the mean hospital stay were calculated per 100,000 population. Mortality refers to inpatient mortality and does not consider the specific death cause.
In order to correlate the rate of hospitalization with the seasonal pattern the mean temperature by month is reported. Temperature data were supplied by the Regional Agency for environmental prevention and protection and derived from 14 monitoring stations located in different areas of the Veneto Region: 12 on plain (<300 m) and 2 on hill (300-600 m).
The direct costs associated to RVGE hospitalisations were estimated through DRG (Diagnosis Related Group) reimbursement rates. Rotavirus gastroenteritis has been referred to the DRG code 184 (esophagitis, gastroenteritis, and miscellaneous digestive disorders, age < 18) by considering only the first diagnosis. According to the Veneto regional DRG reimbursement system (HCFA-DRG, 24th edition) the estimated cost of each RVGE hospital admission is 1,262 €.
The quantitative variables are expressed as the mean and the standard deviation (SD). The Odds Ratio (OR) was used to analyse variables such as age, sex and hospital stay, and the Chi square test for trend to analyse the seasonal pattern. A P value < 0.05 was considered statistically significant.
The Hospital Services of the Veneto Region collect HDD. The data contained is recorded with the patient's consent and can be used as aggregated data for scientific studies without further authorizations. Furthermore the study complies with the Declaration of Helsinki and with the Italian Law Decree n. 196/2003 to protect personal data.
Over the 8-year study period, a total of 26,202 hospital discharges due to infectious gastroenteritis were registered (67.1 cases per 100,000 population). The mean hospital stay was 4.7 ± 5.7 days.
Of these hospitalisations, 14,201 (54.2%) occurred among children aged ≤5 years. Hospital rate among children was significantly higher than that in other age groups (OR = 20.8; [95% confidence interval: 20.30, 21.33]; p < 0.05) and the mean hospital stay halved (3.3 ± 2.4 days vs. 6.5 ± 5.7 days; p < 0.05).
Excluding AGE cases of unspecified etiology (37.8%), a total of 28.6% of all discharges due to AGE of specified etiology in children aged ≤5 years were attributable to RVGE.
The proportion of hospital discharges due to rotavirus gastroenteritis in different age groups was examined in order to assess age-specific rotavirus disease burden (Table 1). The majority of cases were reported among children ≤5 years, in particular infants ≤1 year which registered a significantly higher hospital rate and mean hospital stay than the other age groups (p < 0.05). During the study period 1 death occurred in a 2-year-old male.
Table 2 shows the number of RVGE discharges, the mean hospital stay and hospital rate per 100,000 among children aged ≤5 years: minimal variations of the mean hospital stay were accounted against a significant hospital rate reduction (Chi-square for trend = 116.1; p < 0.05).
Most RVGE cases occurred during the rotavirus season; infections peaked in winter and spring and were lower in summer (Figure 1), with 53.9% of discharges occurring in February-April and 21.4% in March.
The incidence of RVGE admissions in the Veneto Region among children aged ≤5 years was 195.8 per 100,000, ranking as the first cause of acute gastroenteritis hospitalisation for this age group. The mean hospital stay is equal to 3.5 days.
Over the 8-year study period, the economic impact of RVGE varied between 460,630 € and 1,009,600 €. Overall the cost of hospital admission was 5,730,742 € and the 91% of these were used for children ≤5 years.
The incidence of rotavirus infection in Italy seems substantially underestimated. As in most European countries detection of rotavirus is not notifiable so disease estimates are based on hospital discharge data . A recent European model estimated about 10,000 hospitalisations, 80,000 physician visits, 320,000 episodes and 11 deaths occurring each year in Italy .
Our RVGE hospitalisation updated assessment confirms that rotavirus is a major cause of AGE among children aged ≤5 years, accounting 91% of RVGE cases.
The overall rate of hospitalisation for RVGE in our region among children aged ≤5 years is lower than the European mean (198 per 100,000 versus 300 per 100,000) and comparable with analogous studies conducted in other Italian regions [13–15]. However, the comparison with studies using national HDD should be made with caution because the timeframe, the at-risk population and the geographical districts do not overlap.
The mean hospital stay, equal to 3.5 days, is shorter than the European mean (4.8 days) but lies within the European range (2-9.5 days) . Rotavirus gastroenteritis showed a considerable burden of hospital admissions and a clear seasonal distribution, with peak incidence from winter to spring as highlighted in other European countries [17, 18].
Although most of rotavirus infections are successfully treated in a primary care setting, hospitalisation-related costs account for 80% of the budget destined to rotavirus therapy. A recent study assessed direct medical costs for the Italian Health System being around 30 million euro per year . Our study reports that DRG costs associated to hospital admissions due to RVGE are lower than the European mean. European data on the expenditure of rotavirus disease showed that hospital admission is a main cost driver, but non-medical costs are not negligible . However, our study does not estimate social costs, indirect costs and family expenditure costs.
In Italy the national vaccination programme does not include rotavirus universal vaccination for newborns despite safe and effective attenuated rotavirus vaccines [Rotarix (GlaxoSmithKline Biologicals s.a.) and RotaTeq (Sanofi Pasteur MSD, SNC)] have been available in Europe since 2006 [20–22]. In view of the lack of interference with co-administered childhood vaccines both could be included within the existing regional and national immunization programmes. Hence Italian public health authorities should consider the opportunity of offering these vaccines to all newborns within 6 months of age [23, 24]. Several potential strategies to provide rotavirus vaccination are possible. Firstly, an offer concerning children at greater risk of severe illness (i.e.: low birth weight and preterm infants) can be considered for budgetary reasons. However according to a study conducted in the United States even if those risk factors significantly predicted infants at high risk for hospitalization with viral AGE in the first year of life were neither sufficiently sensitive nor specific to be used to create a focused rotavirus immunization policy . Secondly vaccination could be offered free of charge or in co-payment. As other vaccines routinely offered in Italy Rotavirus vaccine can be administered in primary care settings throughout Departments of prevention and/or paediatricians ambulatories. This choice requires a careful evaluation of local health systems organisation, expenditures and expected coverage have to be considered. The decision on which strategy put into practice should be taken by national and regional authorities according to scientific evidence, international recommendations, local epidemiology and primary care organisations. In addition it needs to be preceded by a cost-effectiveness analysis assessing sustainability.
The strengths of the study include a large study population and the provision of epidemiological information on severe RVGE disease in the area which constitutes a valuable baseline for the future assessment of rotavirus vaccine impact.
There are several limitations of our study. Firstly using administrative data could lead to an underestimation of the RVGE incidence because while HDD are characterized by a high specificity, sensitivity could be lower. However in Italy, as in many European countries, rotavirus is not a notifiable disease and estimates are based mainly on hospital discharge data. The HDD is characterized by high specificity and low sensitivity  because of a large number of discharges codified by non-specific codes. The absence of an etiologic diagnosis could be related to budgetary reasons, to not enough sensitive laboratory tests as well as to empirical treatment [2, 17]. Furthermore, the hospitalisation rate could be underestimated because secondary diagnosis of rotavirus gastroenteritis were not taken into account. Some authors demonstrated that the incidence of RVGE admissions grows consistently considering both diagnosis but it is feasible that the second diagnosis have a nosocomial origin [12, 13].
RVGE represents an important cause of paediatric hospitalisation in the Veneto Region, though the impact of RVGE admissions is underestimated, primarily due to a low sensitivity of hospital discharges and an active surveillance system should be implemented. Our data reaffirm the burden of rotavirus hospitalisations in children aged ≤5 years and the potential health benefits of the vaccination introduction that should be offered to all newborns within 6 months of age.
Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI: Global illness and deaths caused by rotavirus disease in children. Emerging Infectious Diseases. 2003, 9: 565-572.
López-de-Andrés A, Jiménez-García R, Carrasco-Garrido P, Alvaro-Meca A, Galarza PG, De Miguel AG: Hospitalizations associated with rotavirus gastroenteritis in Spain, 2001-2005. BioMed Central Public Health. 2008, 8: 109-
Soriano-Gabarró M, Mrukowicz J, Vesikari T, Verstraeten T: Burden of rotavirus disease in European Union countries. The Pediatric Infectious Disease Journal. 2006, 25 (Suppl 1): 7-11. 10.1097/01.inf.0000197622.98559.01.
Vesikari T, Itzler R, Matson DO, Santosham M, Christie CD, Coia M, Cook JR, Koch G, Heaton P: Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries). International Journal of Infectious Diseases. 2007, 11 (Suppl 2): 29-35. 10.1016/S1201-9712(07)60019-8.
Parashar UD, Gibson CJ, Bresse JS, Glass RI: Rotavirus and severe childhood diarrhea. Emerging Infectious Diseases. 2006, 12: 304-306.
WHO: Estimated rotavirus deaths for children under 5 years of age: 2004. [http://www.who.int/immunization_monitoring/burden/Global_national_estimates_2004_deaths_under_age_five_attributable_to_rotavirus_infection_2004.pdf]
Giaquinto C, Van Damme P, Huet F, Gothefors L, Maxwell M, Todd P, da Dalt L, on behalf of the REVEAL Study Group: Clinical consequences of rotavirus acute gastroenteritis in Europe, 2004-2005: the REVEAL study. The Journal of Infectious Diseases. 2007, 195 (Suppl 1): 26-35. 10.1086/516717.
Cook SM, Glass RI, LeBaron CW, Ho MS: Global seasonality of rotavirus infections. Bulletin of the World Health Organization. 1990, 68 (Suppl 2): 171-177.
D'Souza RM, Hall G, Becker NG: Climatic factors associated with hospitalizations for rotavirus diarrhoea in children under 5 years of age. Epidemiology and Infection. 2008, 136: 56-64. 10.1017/S0950268807008229.
Chen KT, Fan SF, Tang RB, Huang YF, Lee PI, Chen PY, Tang CW, Chen HC: Hospital-based study of the economic burden associated with rotavirus diarrhea in Taiwan. Vaccine. 2007, 25: 4266-4272. 10.1016/j.vaccine.2007.02.056.
WHO 2009 position paper: Rotavirus vaccine an update. Wkly Epidemiol Rec. 2009, 84 (51-52): 533-540.
Luquero Alcalde FJ, Eiros Bouza JM, Rubio AP, Bachiller Luque MR, Castrodeza Sanz JJ, Ortiz de Lejarazu Leonardo R: Gastroenteritis by rotavirus in Spanish children. Analysis of the disease burden. European Journal of Pediatrics. 2008, 167: 549-555. 10.1007/s00431-007-0550-8.
Marchetti F, Assael B, Gabutti G, Guarino A, Lopalco PL, Marocco A, Ruggeri F, Titone L, Tozzi A, Rosati GV, Zotti C, Franco E: Monitoring the rate of hospitalization before rotavirus immunization in Italy utilizing ICD9-CM regional databases. Hum Vaccin. 2009, 5 (3): 172-176. 10.4161/hv.5.3.6764.
Gabutti G, Lazzara C, Marsella M, Bergamini M, Malaventura C, Borgna-Pignatti C: Burden of hospitalizations due to Rotavirus infection in Emilia Romagna, Italy. Acta Biomed. 2007, 78 (3): 176-81.
Marocco A, Assael B, Gabutti G, Guarino A, Lopalco PL, Marchetti F, Ruggeri FM, Titone L, Tozzi AE, Vitali Rosati G, Zotti C, Franco E: Ricoveri per enterite da Rotavirus in Italia valutati mediante analisi delle Schede di Dimissione Ospedaliera negli anni 2001-2003. Ig Sanita Pubbl. 2006, 62 (Suppl 2): 215-44.
The Pediatric ROTavirus European CommitTee (PROTEC): The paediatric burden of rotavirus disease in Europe. Epidemiology and Infection. 2006, 134: 908-916. 10.1017/S0950268806006091.
Fischer TK, Nielsen NM, Wohlfahrt J, Paerregaard A: Incidence and cost of rotavirus hospitalizations in Denmark. Emerging Infectious Diseases. 2007, 13: 855-859.
Koopmans M, Brown D: Seasonality and diversity of Group A rotaviruses in Europe. Acta Paediatr Suppl. 1999, 88 (426): 14-19. 10.1111/j.1651-2227.1999.tb14320.x.
Standaert B, Marocco A, Assael B, Gabutti G, Guarino A, Lo palco PL, Marchetti F, Ruggeri FM, Titone L, Tozzi A, Vitali Rosati G, Zotti C, Franco E: Analisi di costo-efficacia della vaccinazione universale in Italia con il vaccino Rix4414 contro i rotavirus. Pharmacoeconomics-Italian Research Articles. 2008, 10: 23-25.
Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, Dallas MJ, Heyse JF, Goveia MG, Black SB, Shinefield HR, Christie CD, Ylitalo S, Itzler RF, Coia ML, Onorato MT, Adeyi BA, Marshall GS, Gothefors L, Campens D, Karvonen A, Watt JP, O'Brien KL, DiNubile MJ, Clark HF, Boslego JW, Offit PA, Heaton PM: Rotavirus Efficacy and Safety Trial (REST) Study Team. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med. 2006, 354 (1): 23-33. 10.1056/NEJMoa052664.
Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, Abate H, Breuer T, Clemens SC, Cheuvart B, Espinoza F, Gillard P, Innis BL, Cervantes Y, Linhares AC, López P, Macías-Parra M, Ortega-Barría E, Richardson V, Rivera-Medina DM, Rivera L, Salinas B, Pavía-Ruz N, Salmerón J, Rüttimann R, Tinoco JC, Rubio P, Nuñez E, Guerrero ML, Yarzábal JP, Damaso S, Tornieporth N, Sáez-Llorens X, Vergara RF, Vesikari T, Bouckenooghe A, Clemens R, De Vos B, O'Ryan M: Human Rotavirus Vaccine Study Group. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med. 2006, 354 (1): 11-22. 10.1056/NEJMoa052434.
Vesikari T, Karvonen A, Prymula R, Schuster V, Tejedor JC, Cohen R, Meurice F, Han HH, Damaso S, Bouckenooghe A: Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet. 2007, 370 (9601): 1757-63. 10.1016/S0140-6736(07)61744-9.
Cortese MM, Parashar UD: Prevention of Rotavirus Gastroenteristis Among Infants and Children Recommandations of the Advisory Committee on Immunization Practices (ACIP). MMRV. 2009, 58 (RR02): 1-25.
Vesikari T, Karvonen A, Prymula R, Schuster V, Tejedor JC, Thollot F, Garcia Corbeira P, Damaso S, Han HH, Bouckenooghe A: Immunogenicity and safety of the human rotavirus vaccine Rotarix co-administered with routine infant vaccines following the vaccination schedules in Europe. Vaccine. 2010, 28 (32): 5272-5279. 10.1016/j.vaccine.2010.05.057.
Newman RD, Grupp-Phelan J, Shay DK, Davis RL: Perinatal risk factors for infant hospitalization with viral gastroenteritis. Pediatrics. 1999, 103 (1): E3-10.1542/peds.103.1.e3.
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2458/10/636/prepub
The authors wish to thank Teolo Metereological Centre. This study is partially supported by a Veneto Region grant.
The authors declare that they have no competing interests.
MS and VB have participated in conceive the study, have made substantial contribution to analysis and interpretation of the data, to revision and final approval of the manuscript. AG, TB, MCB, CB have contributed to interpretation of data and have been involved in drafting the paper. GC and FP have contributed to the acquisition and analysis of data. All authors have read and approved the final manuscript.
Authors’ original submitted files for images
Below are the links to the authors’ original submitted files for images.
About this article
Cite this article
Saia, M., Giliberti, A., Callegaro, G. et al. Hospitalisation for rotavirus gastroenteritis in the paediatric population in the Veneto Region, Italy. BMC Public Health 10, 636 (2010). https://doi.org/10.1186/1471-2458-10-636
- Veneto Region
- Hospital Discharge Database
- RVGE Case
- Severe RVGE